Premium
Buprenorphine in Neonatal Abstinence Syndrome
Author(s) -
Kraft Walter K.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.930
Subject(s) - buprenorphine , medicine , opioid , abstinence , in utero , clinical trial , opioid use disorder , anesthesia , pregnancy , psychiatry , fetus , receptor , biology , genetics
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long‐acting opioid with therapeutic use in medication‐assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure–response relationships and facilitate dose optimization.